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Background: Individuals with end-stage renal disease (ESRD) have excess risk of various cancer types. However, the
total burden of human papillomavirus-related cancers remains unknown.
Methods: We performed a nationwide observational cohort study during 1994–2010.
For each person with ESRD, we sampled 19 population controls (without ESRD) matched on age, gender and
municipality. Participants were followed until first diagnosis of human papillomavirus-related cancer, death,
emigration, or 31 December 2010, whichever came first.
Human papillomavirus-related cancers were extracted from Danish medical administrative databases. We
considered cancers of the cervix, vulva, vagina, penis, anus, and subsets of head and neck cancers as human
papillomavirus-related. We calculated incidence rates of human papillomavirus-related cancer and used Poisson
regression to identify risk factors for human papillomavirus-related cancer.
Results: Among 12,293 persons with ESRD and 229,524 population controls we identified 62 and 798 human
papillomavirus-related cancers, respectively. Incidence rates of human papillomavirus-related- cancer were 102 per
100,000 person-years (95% confidence interval [CI]; 79.5-131) among persons with ESRD and 40.8 per 100,000
person-years (95% CI; 38.1-43.7) among population controls. ESRD patients had 4.54 (95% CI, 2.48-8.31) fold
increased risk of anal cancer and 5.81 fold (95% CI; 3.36-10.1) increased risk of vulvovaginal cancer. Adjusted for age,
comorbidity, and sex, ESRD patients had 2.41 (95% CI; 1.83-3.16) fold increased risk of any human papillomavirus-
related cancer compared with population controls. Compared with dialysis patients renal transplant recipients had
an age-adjusted non-significant 1.53 (95% CI, 0.91-2.58) fold higher risk of human papillomavirus-related cancer.
Conclusions: Persons with ESRD have excess risk of potentially vaccine-preventable human papillomavirus-related
cancers.* Correspondence: larsdalg@rm.dk
1Department of Infectious Diseases, Aarhus University Hospital, Aarhus,
Denmark
Full list of author information is available at the end of the article
© 2013 Skov Dalgaard et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Skov Dalgaard et al. BMC Nephrology 2013, 14:137 Page 2 of 10
http://www.biomedcentral.com/1471-2369/14/137Background
Oncogenic types of human papillomavirus (HPV) can
cause cancer of the cervix, vagina, vulva, penis, anus,
and a subset of cancers of the head and neck [1-3].
Among persons infected with human immunodefiency
virus (HIV), the immunosuppression caused by HIV
contributes to the well described excess risk of HPV-
related cancer [4,5]. In patients with end-stage renal
disease (ESRD) immunosuppressive therapy is used to
prevent transplant rejection among transplant recipients
and occasionally for treatment of the underlying cause
of renal failure among patients on dialysis. Nutritional
deficits and uraemia in itself also contributes to the
complex dysfunction of both the innate and adaptive im-
mune system that characterizes ESRD patients on dialysis
[6-8]. Among transplant recipients, previous studies have
shown a markedly increased risk of a wide range of cancers
including infection-related cancers [9-13]. Among ESRD
patients receiving dialysis, the excess cancer risk appears to
be less pronounced and primarily correlated to cancers
with a known or suspected viral aetiology [10,14,15]. The
immune dysfunction in ESRD patients may explain the
increased risk of infection-related cancers [10,14].
While most studies have focused on heterogeneous
cancer types among patients with ESRD, few studies
have assessed the total burden of HPV-related cancers.
In light of the recent development in prophylactic HPV
vaccination, the interest in HPV-related cancers has
been renewed. Vaccines against the two most important
oncogenic types of HPV (16 and 18) are now licensed.
Among younger healthy individuals HPV vaccination
lowers the risk of pre-cancer lesions of the cervix and
the risk of anal, vulva, vaginal, and penile infections,
with the HPV-types included in the vaccines [16-20].
Further, research in novel vaccines for treatment of
existing lesions caused by HPV has shown promising re-
sults [21].
A recently published large American cohort study found
no increased risk of cervical cancer among solid organ
transplant recipients, which contrasts the findings reported
by Vajdic and colleagues among Australian kidney trans-
plant recipients [9,10]. These findings may be explained by
differences in screening procedures prior to transplantation
and by differences in study populations. In several studies,
HPV-related cancer diagnoses have been grouped with
non-HPV-related cancer diagnoses [10-14,22].
The benefit and cost-effectiveness of HPV immu-
nization will depend on the total burden of HPV-related
cancer, the proportion of ESRD patients with active HPV
infection at the time of vaccination, and the immunoge-
nicity of the vaccines among these patients. Thus, im-
proved knowledge of the epidemiology of HPV-related
cancers among ESRD patients are of great importance for
the decisions of “if” “who”, and “when”, to vaccinate.The main objectives of this Danish nationwide population-
based cohort study were to compare the risk of HPV-
related cancers in the general population with that of
patients with ESRD, and to identify risk factors for HPV-
related cancers in patients with ESRD.
Methods
Study design and setting
We performed a population-based, observational cohort
study among ESRD patients in Denmark during 1 January
1994–31 December 2010. In Denmark, the prevalence of
chronic renal failure requiring renal replacement therapy,
i.e. dialysis or transplantation is 0.08% and in 2010 ap-
proximately 4,700 persons were living with ESRD [23].
Treatment of ESRD is restricted to 15 hospital depart-
ments, 4 of which had status as transplantation centers
during the study. In Denmark, the tax-funded health care
system provides free of charge treatment for all patients
with ESRD. Since 1990, all departments treating ESRD pa-
tients report data to the Danish Nephrology Registry
(DNR). The DNR contains information on e.g. cause of
renal disease, date of first replacement therapy for ESRD,
treatment modality, and treatment complications. The
DNR has a completeness of 97.2% [24].
Participants
We defined ESRD patients as patients treated with renal
replacement therapy (dialysis or transplantation) for at
least 90 days. Prevalent ESRD patients as of 1 January
1994 or incident thereafter, who were resident in
Denmark and at least 14 years of age at the time of their
first treatment for ESRD were identified in the DNR and
included in the study. For each ESRD patient we sam-
pled 19 population controls matched on age (within
1 year of date of birth), municipality, and gender from
the Civil Registration System (CRS) at the day of inclu-
sion in the ESRD registry. Since 1968, the CRS has pro-
vided all Danish citizens with a unique 10 digit civil
registration number, which allows for accurate linkage
between different databases [25].
We obtained information on vital status, sex, date of
birth, date of death, and residence of ESRD patients and
their population controls from the CRS, which is
updated within a week of person’s birth, death, or emi-
gration. Population controls were used for comparative
analysis. ESRD patients and population controls diag-
nosed with HPV-related cancer prior to study participa-
tion were excluded.
Variables and data sources
Definition of HPV-related cancer
We classified cancers of the anus, vulva, vagina, cervix,
penis, and a subset of head and neck cancers as HPV-
related [2]. Cancer diagnoses were coded according to
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eases (ICD-10) as outlined in Table 1. For head and neck
cancers, we used the classification published by Ryerson
et al. in order to restrict our analyses to the cancer sites
most strongly associated with HPV [26].
Identification of patients with HPV-related cancer
The Danish National Registry of Patients (DNRP) con-
tains information of all hospital admissions in Denmark
since 1977 and all outpatient contacts since 1995
[27,28]. Variables include civil registration number, dates
of admission and discharge, and discharge diagnoses.
Since 1994, diagnoses have been coded according to the
ICD-10. During 1977–1993 the 8th version (ICD-8) was
used. The Danish Cancer Registry (DCR) contains data
on incident cancers in Denmark since 1943.The DCR is
nationwide and contains ICD-10 diagnoses (as part of
the ICD-0 classification) since 1978 [29]. Original diag-
noses from 1978–1993 have been electronically recoded
from ICD-7 to ICD-10. We classified the earliest date of
a HPV-related cancer diagnosis as the date of the first
diagnosis of a HPV-related cancer. We used both the
DNRP and the DCR to identify HPV-related cancer. In a
random sample of 100 persons with a HPV-related can-
cer, 75% were identified in the DCR while 25% was iden-
tified in the DNRP alone.
Age, sex, cause of renal failure and comorbidity
Based on date of birth in the CRS we generated a time
varying covariate age (14–49, 50–64, and ≥65 years). In-
formation on cause of renal failure was obtained from
the DNR database. Causes of renal failure were catego-
rized as follows: Glomerulonephritis, Diabetes Mellitus
types I and II, Chronic Interstitial Nephritis, Hyperten-
sion and Chronic renal failure without specification,
Polycystic Kidney Disease, Vasculitis, and Other. The
Charlson’s Comorbidity index (CCI) was used to quan-
tify comorbidity. The CCI is a weighted index based on
19 major disease categories each assigned with a weight
(1, 2, 3, or 6). CCI is a validated measure of co-Table 1 Diagnoses in the 10th edition of the International
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abased on classification used by Ryerson et al.[26].morbidity [30,31]. We did not include renal diagnoses in
the CCI score in this study. Based on discharge diagno-
ses obtained from the Danish National Registry of Pa-
tients (DNRP) we calculated CCI for each ESRD patient
and his/her population controls at the time of study
entry. We used CCI at the time of first treatment for
ESRD to create 3 levels of co-morbidity: low (CCI = 0)
medium (CCI = 1-2) and high (CCI ≥3).
Statistical analysis
Time at risk
For each ESRD patient and his/her population controls
time at risk started at 1 January 1994 or the date of first
treatment for ESRD, whichever came last. Time at risk
ended at the date of first diagnosis of a HPV-related can-
cer, death, emigration, or 31 December 2010, whichever
came first.
Incidence rates
We calculated incidence rates (IRs) and 95% confidence
intervals (95% CIs) of HPV-related cancers with and
without stratification for the five anatomic regions
outlined in Table 1. We calculated incidence rates of
HPV-related cancer with and without prevalent ESRD
patients and only minor differences in risk estimates
were found. We therefore chose to include both preva-
lent and incident ESRD patients in our final analysis.
Temporal changes in IRs of first episodes of HPV-
related cancers were analysed in following intervals
1994–97, 1998–01, 2002–2005, and 2006–2010. Inci-
dence rate ratios (IRRs) with corresponding 95% CIs
were calculated for comparison between ESRD patients
and population controls. In a separate analysis IRs of
HPV-related cancer were compared among two sub-
groups of ESRD patients: 1) transplant recipients with
functioning grafts and 2) dialysis patients. In these ana-
lyses, renal replacement therapy i.e. dialysis and trans-
plant recipients with functioning grafts was treated as a
time varying covariate. Thus, if the mode of renal re-
placement therapy was changed during follow-up, a per-
son would contribute to risk time in both subgroups.
IR’s were compared between the two subgroups with
and without stratification for age. For the latter analyses
Poisson regression was used: Adjustment for sex, comor-
bidity and cause of renal failure only caused minor effect
on the risk estimates and therefore neither of these vari-
ables were included in the final analyses.
Risk factor analysis
We used Poisson regression to identify potential risk fac-
tors for HPV-related cancer among ESRD patients. The
following variables were included: Sex, age (14–49, 50–
64, and ≥65 years), and the CCI index score. Among the
study population 24 patients with ERSD and 227
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positive persons in our study population, only two
(population controls) developed a HPV-related cancer
during the study period and we therefore chose not to
adjust for HIV status in our analyses. While age and sex
are well-known risk factors for cancer, the CCI is not an
established risk factor for HPV-related cancer. We there-
fore calculated adjusted risk estimates with and without
the CCI. In the risk factor analysis, we did not stratify
for anatomical location of HPV-related cancers.
We used the Stata® statistical software (Statacorp,
College Station, Texas) version 11.0 for statistical ana-




We excluded 92 ESRD patients (and their matched con-
trols) diagnosed with a HPV-related cancer prior to
study participation. A total of 442 population controls
diagnosed with HPV-related cancer prior to study par-
ticipation were also excluded. Persons who died or emi-
grated before the study period did not contribute to riskTable 2 Baseline characteristics of the study population
End-stage renal dise
Number of participants 12,293
Male sex, n (%) 7,683 (62.5)








Cause of end-stage renal disease
Glomerulonephritis 1,751 (14.2)
Diabetes I + II 2,595 (21.1)
Chronic interstitial nephritis 1,496 (12.2)
Hypertension and Chronic renal
failure without specification 4,019 (32.7)




No transplantation 8,978 (73.0)
≥1 Transplantation 3,315 (27.0)
aIndexdate: Date of first treatment for end-stage renal disease and date of sampling
bThree levels of comorbidity was created based on Charlson comorbidity index sco
(CCI = 0), “Medium” CCI 1–2, and “High” CCI > 2. Renal diagnosis was not included intime. Consequently 12,293 ESRD patients and 229,524
population controls were included in the study.
Descriptive data
Table 2 displays basic characteristics of the study popu-
lation. Males comprised 62.5% of the ESRD population.
The 12,293 ESRD patients and 229,524 population con-
trols provided 60,813 and 1,955,900 person-years of risk
time respectively.
Median time at risk was 3.35 (maximum 17.0) years
and 7.85 (maximum 17.0) years among ESRD patients
and population controls, respectively. Median age of
ESRD patients at the date of their first treatment with
renal replacement therapy was 61.6 years.
Outcome data
During the study period we identified a total of 62 cases
of HPV-related cancers among ESRD patients and 798
cases among population controls (Table 3).
Main results
Table 3 outlines crude IRs of first diagnosis of HPV-



















re (CCI) at the date of first treatment with renal replacement therapy “Low”
the CCI score in this study.
Table 3 Crude incidence rates of first episodes of Human papillomavirus-related cancers among persons with end-
stage renal disease and population controls during 1994-2010
Anatomical region Group No. Risk timea Crude IRb (95% CI) IRR (95% CI) P value
Head and neckc ESRD 18 0.608 29.6 (18.6-47.0) 1.77 (1.10-2.84) 0.02
Controls 328 19.559 16.8 (15.1-18.7)
Cervicald ESRD 12 0.229 52.3 (29.7-92.1) 1.81 (1.01-3.23) 0.05
Controls 221 7.644 28.9 (25.3-33.0)
Vulva and vaginad ESRD 15 0.229 65.4 (39.4-108) 5.81 (3.36-10.1) <0.001
Controls 86 7.644 11.3 (9.11-13.9)
Penise ESRD 5 0.379 13.2 (5.49-31.7) 2.02 (0.82-4.98) 0.1
Controls 78 11.915 6.55 (5.24-8.17)
Anal ESRD 12 0.608 19.7 (11.2-34.7) 4.54 (2.48-8.31) <0.001
Controls 85 19.559 4.35 (3.51-5.38)
All HPV-related ESRD 62 0.608 102 (79.5-131) 2.50 (1.93-3.24) <0.001
Controls 798 19.559 40.8 (38.1-43.7)
Abbreviations: HPV Human papilloma virus, No. number of HPV-related cancers, CI confidence interval, IR incidence rate, IRR incidence rate ratio, ESRD end-stage
renal disease.
a 100,000 years.
b Per 100,000 person-years.
c HPV-related head and neck cancer sites as outlined in Table 1.
d Only females contributed to risk time.
e Only men contributed to risk time.
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related cancer was 102 (95% CI, 79.5-131) per 100,000
person-years and 40.8 (95% CI, 38.1-43.7) per 100,000
person-years among ERSD patients and population con-
trols, respectively. The IR of all HPV-related cancers
among ESRD patients was 2.50 (95 CI%, 1.93-3.24) fold
higher than among population controls. The IRs of first
episode of HPV-related cancer were significantly higher
among ESRD patients compared to the control popula-
tion in 4 of 5 anatomical regions, most markedly for anal
cancer (IRR 4.54; 95% CI, 2.48-8.31) and vulva/vaginalFigure 1 Temporal trends in crude incidence rates of human papillom
disease and a matched background population.cancer (IRR 5.81; 95% CI, 3.36-10.1). The IRRs of cer-
vical cancer and cancers at HPV-related head & neck
sites were 1.81 (95% CI, 1.01-3.23) and 1.77 (95% CI,
1.10-2.84) respectively. Figure 1 shows a modest non-
significant increase in IRs of first diagnosis of HPV-
related cancers among ESRD patients over the study
period (p = 0.57), whereas IRs among population con-
trols remained stable.
Among ESRD patients, transplant recipients with
functioning grafts had an unadjusted 1.83 (95% CI, 1.11-
3.01) fold higher risk of HPV-related cancer comparedavirus-related cancers among patients with end-stage renal
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1.53 (95% CI, 0.91-2.58) comparing transplant recipients
to dialysis patients (Table 4).
Risk factors for HPV-related cancer
Table 5 illustrates potential risk factors for HPV-related
cancers among ESRD patients and population controls.
Among ESRD patients female sex (IRR 2.11; 95% CI,
1.27-3.48) and age 50–64 years (IRR 2.39; 95% CI, 1.30-
4.39) were risk factors for HPV-related cancer. Among
population controls, female sex (IRR 1.54; 95% CI,
1.34-1.77), age (50–64 years: IRR 2.14; 95% CI, 1.67-
2.75 and ≥65 years: IRR 2.75; 95% CI, 2.18-3.48) and
co-morbidity level (medium: IRR 1.41; 95% CI 1.18-1.69
and high: IRR 2.49 (95% CI; 1.89-3.28) were all risk fac-
tors for HPV related cancer. Interestingly, the IR of
HPV–related cancer among ESRD patients was mark-
edly higher at age 50–64 years compared to age 14–
49 years and age ≥65 years. When adjusted only for age
and sex we found an IRR of 2.76 (95% CI, 2.13-3.58) of
HPV-related cancer compared to population controls.
Discussion
In this nationwide, population-based study, we found
that the risk of HPV-related cancer overall was 2.5 fold
increased among ERSD patients compared to matched
population controls. Interestingly, ESRD patients had a
more than fourfold increased risk of anal cancer and fe-
male ESRD patients had a nearly six fold increased risk
of cancers of vulva and vagina. Major risk factors for
HPV-related cancer were age and gender. When ad-
justed for age, transplant recipients (with a functioning
graft) had a modest 1.53 fold increased risk of HPV-
related cancer compared to dialysis patients. Although
not significant we cannot rule out an increased risk of
HPV-related cancer among transplant recipients due to
the low number of cancers in the two groups.
Our study is one of few population-based studies to
investigate the burden of HPV-related cancer amongTable 4 Risk of human papillomavirus-related cancer among
replacement therapy
Dialysis Graf
No. IR (95% CI)a No
Head and neckb 8 21.4 (10.7-42.7) 10
Vulva and vagina 5 35.0 (14.5-84.0) 10
Cervix 8 55.9 (28.0-112) 4
Anal 5 13.3 (5.55-32.1) 7
Penis 3 13.0 (4.18-40.2) 2
All HPV-related 29 77.4 (53.8-111) 33
Abbreviations: No. number cancers, CI confidence interval, IR incidence rate, IRR una
a Per 100,000 person-years.
b HPV-related head and neck cancer subsites as outlined in Table 1.unselected individuals with ESRD. The major strengths
of our study are the use of population-based nationwide
cohorts with high degrees of completeness and minimal
loss to follow-up. Because we considered only the first
diagnosis of HPV-related cancer our estimates were not
biased by multiple episodes of HPV-related cancer oc-
curring in highly susceptible individuals. Further, HPV-
related cancer may increase the risk of development of
ESRD and therefore lead to increased risk of HPV-
related cancer among ESRD patients.
Our study had some limitations. The relatively low
number of HPV-related cancer limited our opportunities
to adjust for potential risk factors and the width of con-
fidence interval complicates the comparison between
transplant recipients and patients on dialysis. However,
large follow-up time and careful matching yielded esti-
mates of high statistical precision and validity.
We did not have access to information on use of im-
munosuppressive drugs among ESRD patients and there-
fore we could not assess the effect of individual drug
regimens on the risk of HPV-related cancer. Likewise,
we were unable to identify dialysis patients receiving im-
munosuppressive therapy for their renal disease.
Whereas HPV is considered mandatory for development
of cervical cancer the etiological fraction of HPV differ
among other cancer types considered as HPV-related. If
the etiological fractions of HPV are higher among ESRD
patients than among population controls this may have
led to underestimation of the importance of HPV among
ESRD patients in our study. We restricted our analysis
to the cancers most strongly associated with HPV in
order to minimize the risk of misclassification of non-
HPV-cancers as HPV-related. Whereas diagnoses in hos-
pital discharge registries may be revised and therefore
not reflect true cancers, cancer registries have a degree
of underreporting. We chose to include cancers identi-
fied solely in the DNRP in this study. In the DCR, ICD-7
diagnoses were used until 2004. Subsequently diagnoses
have been electronically recoded from ICD-7 to ICD-10.patients with end-stage renal disease by type of renal
t function
IR (95%CI)a IRR (95% CI) P value
42.9 (23.1-79.6) 2.00 (0.71-5.85) 0.1
116 (62.3-215) 3.31 (1.13-9.69) 0.03
46.3 (17.4-123) 0.83 (0.25-2.75) 0.8
30.0 (14.3-62.9) 2.25 (0.71-7.08) 0.2
13.6 (3.40-54.4) 1.05 (0.18-6.29) 0.9
141 (100–198) 1.83 (1.08-3.12) 0.02
djusted incidence rate ratio, IR incidence rate.
Table 5 Incidence rates of first episodes of human papillomavirus-related cancers by potential risk factors among
persons with end stage renal disease and population controls during 1994-2010
Variable No. IRa (95% CI) Unadjusted IRR (95% CI) Adjusted IRRb (95% CI)b Pc
Total
Controls 798 40.8 (38.1-43.7) 1(reference) 1 (reference) -
ESRD 62 102 (79.5-131) 2.50 (1.93-3.24) 2.41 (1.83-3.16) <0.001
Sex Controls
Men 404 33.9 (30.8-37.4) 1 (reference) 1 (reference) -
Women 394 51.5 (46.7-56.9) 1.52 (1.32-1.75) 1.54 (1.34-1.77) <0.001
ESRD
Men 27 71.3 (48.9-104) 1 1 -
Women 35 153 (110–213) 2.14 (1.30-3.54) 2.11 (1.27-3.48) 0.004
Age (years) Controls
14-49 83 18.8 (15.2-23.3) 1 (reference) 1 (reference) -
50-64 242 40.2 (35.5-45.7) 2.14 (1.67-2.75) 2.11 (1.64-2.71) <0.001
≥ 65 473 51.8 (47.3-56.7) 2.75 (2.18-3.48) 2.51 (1.98-3.18) <0.001
ESRD
14-49 15 73.0 (44.0-121) 1 (reference) 1 (reference) -
50-64 34 165 (118–231) 2.26 (1.23-4.15) 2.39 (1.30-4.39) 0.005
≥ 65 13 66.0 (38.3-114) 0.90 (0.43-1.90) 1.03 (0.48-2.19) 0.9
Comorbidity level d Controls
Low 591 36.8 (34.0-39.9) 1 (reference) 1 (reference) -
Medium 152 52.1 (44.4-61.1) 1.41 (1.18-1.69) 1.23 (1.02-1.47) 0.03
High 55 91.7 (70.4-119) 2.49 (1.89-3.28) 2.12 (1.60-2.81) <0.001
ESRD
Low 40 130 (95.1-177) 1 (reference) 1 (reference) -
Medium 15 98.4 (59.3-163) 0.76 (0.42-1.37) 0.77 (0.42-1.41) 0.4
High 7 47.5 (22.6-99.6) 0.37 (0.16-0.82) 0.39 (0.17-0.87) 0.02
Abbreviations: No number of human papillomavirus-related cancers, IR incidence rate, IRR incidence rate ratio.
a Per 100,000 person-years.
b Adjusted for all variables in the table.
c Calculated for the corresponding adjusted incidence rate-ratios.
d 3 levels of comorbidity was created based on Charlson comorbidity index (CCI) score at the date of first treatment with renal replacement therapy “Low”
(CCI = 0), “Medium” CCI 1–2, and “High” CCI > 2. Renal diagnosis was not included in the CCI score in this study.
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cause some misclassification during the recoding process
due to the very specific cancer sites (ICD-10) used to
identify these cancers. In these cases DNRP may be
more accurate than the DCR. In the remaining cases the
validity of cancers identified in the DNPR may be lower
than cancers identified in the DCR. Previous studies
have indicated high completeness of the DCR and DNP
for breast cancer [32], urological cancers [33], colorectal
cancers [34], and haematological cancers [35]. To ensure
inclusion of all HPV-related cancers we therefore used
both the DCR and DNPR.
In a previous study, Birkeland and colleagues reported
a 8.6 fold increased risk of cervical cancer among female
kidney transplant recipients [13]. In a more recent study,
Vajdic and colleagues reported a two and a half foldincreased risk of cervical cancer among both transplant
recipients and patients on dialysis for ESRD. Shebl et al.
reported a 2.12 fold increased risk of cervical cancer
among elderly ESRD patients on dialysis [15]. We found
a 1.78 fold increased risk of cervical cancer among fe-
male ESRD patients and incidence rates of cervical can-
cer were similar among dialysis patients and patients
with functioning grafts. In Denmark, nationwide system-
atic screening for cervical cancer and pre-cancer lesions
of the cervix was implemented during the early 1990’s
[36,37]. Our results therefore reflect the risk of cervical
cancer in a setting with systematic cervical screening of-
fered free of charge for the study population. A recent
American study by Engels and colleagues reported no
increased risk of cervical cancer among solid organ
transplant recipients [9].
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transplant recipients standardized incidence rate-ratios
reported by Engels were in concordance with our fin-
dings in ESRD patients and the findings by Vajdic and
colleagues [9,10].
The cancer risk among dialysis patients is less well
studied than among kidney transplant recipients. A pre-
vious study suggested that dialysis patients had a modest
1.18 fold increased cancer risk overall, whereas the risk
of cervical cancer, penile cancer, and cancer of the oral
cavity, was between 1.7 and 4.0 fold increased [14].
However, incomplete data on cancer diagnoses and sig-
nificant variation in transplantation rates and renal diag-
noses may have affected these results [14,38]. In a more
recent study, Van Leeuwen et al. reported a rapid decline
in risk of non-Hodgkin’s lymphoma, melanoma, and
cancer of the lip, among kidney transplant recipients fol-
lowing transplant failure and reinstitution of dialysis
[39]. Unfortunately, the study had only 7,104 person-
years of follow-up during dialysis following transplant
failure and only one case of HPV-related cancer was
identified among graft-loss patients with consequent un-
certainty in risk estimates for HPV-related cancer. Our
results suggest that dialysis patients are at increased risk
of HPV-related cancer which is in concordance with
findings by Vajdic and colleagues [10].
Overall we estimate the external validity of our results
to be high due to the population based design, choice of
study period, the high quality of the databases used for
the study, and the overall concordance with existing lit-
erature. Nevertheless differences in renal populations
exist and should always be taken into account when ap-
plying our results to other renal populations.
Our results suggest that efforts to prevent HPV-
related cancer should focus on dialysis patients as well
as transplant recipients. Despite nationwide free of
charge screening programs for cervical cancer, ESRD pa-
tients are still at increased risk of these cancers. Whether
attendance to cervical screening differs among ESRD pa-
tients and the control population in our study population
is unknown. Given the high IRs of vulvovaginal cancer it
is important that the clinicians performing cervical smears
are also observant to early signs of these cancers in ESRD
patients For non-cervical HPV-related cancers no vali-
dated screening programs are currently available. Anal
cancer screening have been considered among HIV
infected men, but low sensitivity of cytology, high preva-
lence of anal intraepithelial neoplasia, and uncertainty of
the natural history of these lesions complicates develop-
ment of a screening program. For these cancers, early de-
tection therefore relies on clinician’s and patients’
awareness on early signs and symptoms of cancer.
Two HPV vaccines are commercially available [40,41].
Both vaccines cover the most important oncogenicHPV-serotypes16 and 18, which are considered respon-
sible for 70% of cervical cancers and the majority of
non-cervical cancers caused by HPV [2]. In healthy indi-
viduals HPV-vaccination can prevent reactivation/re-
infection with vaccine HPV serotypes to which they
were seropositive and DNA negative at study enrolment
[42,43]. The vaccines have no therapeutic effect against
existing HPV-related lesions [17,44,45]. Neither of the
vaccines has been formally tested in persons with ESRD
but studies among HIV infected men and children have
reported high rates of seroconversion. Our study illus-
trates that the total burden of HPV-related cancers is
low among ESRD patients. Further the proportion of
cancers caused by HPV infection prevalent at the time
of diagnosis of ESRD patients is to our knowledge un-
known. If this proportion is high the benefit of HPV vac-
cination is likely to be limited.
Conclusions
Our study demonstrates that persons with ESRD have a
markedly increased risk of HPV-related cancer compared
to matched population controls. Patients with end-stage
renal disease had a 4.5 fold increased risk of anal cancer
and an almost 6 fold increased risk of vulvovaginal cancer.
Transplant recipients only had a modest non-significant
1.53 fold increased risk of HPV-related cancer compared
to dialysis patients. Age and female sex were most import-
ant risk factors for HPV-related cancer among persons
with end-stage renal disease. Future studies of safety, im-
munogenicity, and efficacy of prophylactic HPV-vaccines
among ESRD patients are needed to clarify the benefit of
HPV-vaccination in this population.
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